Circulate Health: 10 Key Things You Must Know

Overview

Circulate Health is an innovative longevity-focused healthcare startup that pioneers advanced therapeutic plasma exchange (TPE) treatments aimed at extending human healthspan and potentially reducing biological aging. Founded with a strong scientific foundation, the company collaborates with leading research institutions to translate decades of medical plasma exchange use into cutting-edge longevity solutions. Circulate Health’s therapeutic approach has attracted significant attention for its potential to not only mitigate inflammation and age-related biomarkers but also rejuvenate cellular processes, offering hope for healthier, longer lives. This article explores ten key aspects of Circulate Health’s story, technology, research, and future prospects.

1. Origins and Leadership

Circulate Health was founded on the scientific research of Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, a world-renowned geroscientist dedicated to aging biology. The company is led by CEO Dr. Brad Younggren, a seasoned physician with decades of experience in medicine and healthcare startups. Founded in stealth mode, Circulate officially launched in 2024 and quickly gained traction by translating plasma exchange science into practical, outpatient health services that can be accessed via partner clinics across the United States.

2. Therapeutic Plasma Exchange Technology

At the heart of Circulate Health’s service is the therapeutic plasma exchange (TPE) procedure, a medical technique that removes a patient’s plasma—the liquid portion of blood carrying proteins, antibodies, and inflammatory molecules—and replaces it with a substitute fluid such as albumin. This process is designed to remove harmful biological factors that accumulate with aging and contribute to chronic diseases, effectively providing a “circulatory system tune-up” by reducing systemic inflammation and molecular debris associated with aging.

3. Scientific Validation and Clinical Research

Circulate Health has collaborated extensively with the Buck Institute and independent scientists to conduct pioneering clinical trials exploring TPE's impact on biological aging. Notably, a published study in the journal Aging Cell reported that TPE treatments, especially when combined with intravenous immunoglobulin (IVIG), reduced participants’ biological age by an average of 2.6 years based on multiomics biomarkers. Though preliminary and small-scale, these results have been hailed as the first rigorous human evidence supporting plasma exchange as a longevity intervention.

4. Clinical Application and Service Model

Circulate operates by partnering with over two dozen longevity clinics across multiple U.S. states, delivering the TPE treatment alongside specialized protocols and trained nursing staff. Each session typically lasts about two hours and costs between $8,000 and $10,000. The company aims to expand its network to over 50 clinics domestically and internationally by the end of 2025, making this advanced therapy increasingly accessible to health-conscious individuals seeking to proactively manage their aging process.

5. Safety, Risks, and Criticisms

While TPE is an established medically effective treatment for certain autoimmune and blood disorders, its use for longevity purposes remains investigational. Experts caution that the evidence for long-term health benefits linked to aging remains inconclusive, and the procedure carries risks including infections, anemia, and other complications. Medical authorities urge larger, longer-term clinical trials to confirm effectiveness and safety before widespread adoption. Circulate acknowledges these limitations and emphasizes ongoing research and patient monitoring.

6. Funding and Investment

Circulate Health raised $12 million in seed funding in mid-2025, led by prominent venture capital firms such as Khosla Ventures, Seaside Ventures, and CSC Ventures. This capital injection supports further clinical research, technology development, and geographic expansion of its clinic network. The investment underlines significant market interest and confidence in the company's mission to pioneer scientifically validated longevity therapies.

7. Impact on Longevity and Aging Science

By focusing on removing deleterious plasma components implicated in inflammation and cellular dysfunction, Circulate Health’s TPE therapy represents a novel approach to addressing the hallmarks of aging at the molecular level. The strategy exemplifies a shift in the longevity field from treating age-related diseases to modulating biological aging itself. If substantiated by future studies, this could transform preventive healthcare paradigms and extend healthy lifespan substantially.

8. Collaboration with Research Institutions

Circulate Health benefits from a strong alliance with the Buck Institute for Research on Aging and other experts, including Dr. David Furman, who led the company’s clinical trials. Such partnerships provide critical scientific rigor, access to cutting-edge biomarker technologies, and a collaborative framework for innovation. This alliance enhances the company’s credibility and helps translate basic geroscience into practical therapies.

9. Market Position and Competitors

Circulate Health operates in the emerging and rapidly evolving longevity market, facing growing competition from other clinics offering blood-cleaning or rejuvenation treatments, like MaxWell Clinic and Next Health. However, Circulate differentiates itself through proprietary protocols, data-driven research publications, and its strategic focus on multiomics assessments of biological age. The company is positioned as a leader in scaling plasma exchange services specifically tailored for aging intervention.

10. Future Prospects and Challenges

Looking forward, Circulate Health plans to increase the availability of its services in new locations and expand its scientific studies to validate long-term health benefits. Challenges remain related to cost reduction, broader clinical acceptance, regulatory approvals, and demonstrating tangible improvements in quality of life and longevity. The company is hopeful that continued innovation and evidence accumulation will pave the way for plasma exchange to become a mainstream longevity therapy.

Conclusion

Circulate Health is at the forefront of applying therapeutic plasma exchange technology to the quest for healthier aging and life extension. With strong scientific roots, pioneering clinical research, and growing investor support, the company aims to make a significant impact in the longevity space. While challenges remain in proving definitive benefits and safety, Circulate’s integrative approach to reducing biological age and systemic inflammation offers a promising glimpse into the future of personalized and preventive healthcare. As the science advances, the question remains: could circulating one’s blood through a sophisticated cleansing process become a cornerstone of aging well in the 21st century?